Table 3.
Significantly enriched KEGG signaling pathways.
| Pathway ID | Pathway term | Gene count | FDR |
|---|---|---|---|
| Hsa04066 | HIF-1 signaling pathway | 23 | 2.80E-14 |
| Hsa04151 | PI3K-Akt signaling pathway | 35 | 6.78E-11 |
| Hsa04620 | Toll-like receptor signaling pathway | 21 | 2.06E-11 |
| Hsa04668 | TNF signaling pathway | 27 | 2.14E-17 |
| Hsa05133 | Pertussis | 17 | 2.66E-10 |
| Hsa05142 | Chagas disease (American trypanosomiasis) | 20 | 9.23E-11 |
| Hsa05145 | Toxoplasmosis | 21 | 3.54E-11 |
| Hsa05152 | Tuberculosis | 25 | 1.19E-10 |
| Hsa05160 | Hepatitis C | 22 | 1.19E-10 |
| Hsa05161 | Hepatitis B | 36 | 2.60E-23 |
| Hsa05164 | Influenza A | 25 | 9.23E-11 |
| Hsa05200 | Pathways in cancer | 55 | 8.75E-24 |
| Hsa05205 | Proteoglycans in cancer | 29 | 1.63E-12 |
| Hsa05210 | Colorectal cancer | 17 | 2.08E-11 |
| Hsa05212 | Pancreatic cancer | 21 | 1.43E-15 |
| Hsa05215 | Prostate cancer | 23 | 4.22E-15 |
| Hsa05219 | Bladder cancer | 20 | 1.51E-18 |
| Hsa05220 | Chronic myeloid leukemia | 17 | 1.52E-10 |
| Hsa05222 | Small cell lung cancer | 18 | 2.03E-10 |
| Hsa05223 | Non-small cell lung cancer | 18 | 2.85E-13 |
FDR: false discovery rate.